Bridge to Life Expands Portfolio with VitaSmart Acquisition
Deal News | Dec 18, 2024 | PR Newswire Cision Bridge to Life, Ltd.
In a strategic move to strengthen its position in organ preservation and perfusion technology, Bridge to Life Ltd. has acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A. The acquisition also includes global trademark rights and the ability to register the VitaSmart™ name worldwide, marking a significant milestone for the company in advancing transplant medicine. The VitaSmart™ system has been integral in over 5,000 successful liver perfusions, demonstrating its effectiveness in preserving organs. This acquisition enables Bridge to Life to further expand its product offerings and enhance its enterprise value. CEO Don Webber emphasized that the user-friendly design and minimal monitoring requirements of the VitaSmart™ system make it a game-changer for clinicians, particularly in Europe. The company is preparing for FDA submission in the U.S. and aims to expand access to this transformative technology for U.S. transplant centers by early 2025. Medica S.p.A., based in Italy, is known for its technological innovations in the biomedical sector.
Sectors
- Organ Preservation and Transplant Technology
- Medical Devices and Biotechnology
Geography
- United States – Bridge to Life Ltd. is based in the U.S., and there are plans to introduce the VitaSmart™ system to the U.S. market pending FDA approval.
- Italy – Medica S.p.A., the seller of the VitaSmart™ system, is headquartered in Italy, contributing to its international business operations.
Industry
- Organ Preservation and Transplant Technology – This industry involves the development and commercialization of technologies aimed at improving organ preservation and transplantation outcomes. Bridge to Life Ltd.'s acquisition of VitaSmart™ fits squarely within this industry.
- Medical Devices and Biotechnology – Includes companies that manufacture medical devices and engage in biotechnology research and innovation. Medica S.p.A. operates within this sector by developing advanced products for blood and water purification.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Bridge to Life Ltd. | Acquirer | Company | A leader in organ preservation solutions and perfusion technology. |
| Medica S.p.A. | Vendor | Company | An Italian biomedical and MedTech group known for its innovations in blood and water purification. |
| Don Webber | CEO and President | Person | CEO and President of Bridge to Life Ltd., leading the acquisition strategy for the company. |